Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Biogen financials data including stock price, CreditSafe score, income statement, balance sheet, cash flow, and acquistions and subsidiaries.
Stock Price
$183.5
2024-10-29
Market Capitalization
$26.7 B
2024-10-29
Revenue
$9.9 B
FY, 2025
CreditSafe Score
?
Score changed on Jun 04, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|
| Revenue | 10.2B | 9.8B | 9.7B | 9.9B |
| Cost of goods sold | 2.3B | 2.5B | 2.3B | 2.4B |
| Gross profit | 7.9B | 7.3B | 7.4B | 7.5B |
| Gross profit margin, % | 77.6% | 74.2% | 76.1% | 75.7% |
| General and administrative expense | 2.4B | 2.5B | 2.4B | 2.4B |
| Operating expense total | 4.3B | 6.0B | 5.5B | 4.2B |
| Depreciation and amortization | 365.9M | 240.6M | 446.7M | |
| Pre tax profit | 3.6B | 1.3B | 1.9B | 1.6B |
| Income tax expense | 632.8M | 135.3M | 273.8M | 263.6M |
| Net Income | 3.0B | 1.2B | 1.6B | 1.3B |
| EPS | 20.9 | 8.0 | 11.2 | 8.8 |
Acquisitions & Subsidiaries
| Company name | Date | Deal size |
|---|---|---|
| Lorem | Dec 23, 2021 | $40.0M |
| Ipsum | Jan 18, 2022 | $30.0M |
| Lorem Ipsum | Feb 18, 2022 | $25.0M |
| Dolor | Oct 21, 2021 | $60.0M |
Premium Content only available in Craft’s Intelligence Portal View acquisitions and subsidiaries by company, date, and deal size. Understanding this data enables better supplier & customer negotiations and helps identify potential opportunities or market risks for your firm. Learn more |